March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
7 citations
,
September 1997 in “PubMed”
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
1 citations
,
April 1999 in “The Journal of Urology” 34 citations
,
July 1993 in “PubMed” 12 citations
,
January 1993 in “PubMed”
1 citations
,
January 2015 in “Hair therapy & transplantation” New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
1 citations
,
March 2022 in “British Journal of Clinical Pharmacology” 5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
6 citations
,
December 2016 in “Journal of Dermatology” Dutasteride effectively and safely treats male hair loss for over a year.
March 2023 in “Oxford University Press eBooks”
20 citations
,
May 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
62 citations
,
January 2004 in “PubMed” 5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.
13 citations
,
December 2012 in “Canadian Urological Association Journal” 5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
June 2023 in “Sri Lanka Journal of Menopause” January 2011 in “Bloomsbury Academic eBooks” 20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
August 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride effectively treats hair loss and prostate issues.
10 citations
,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
6 citations
,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.